DiaSorin and Tecan to collaborate in new platform development
(Thomson Reuters ONE) -
Tecan Group AG /
DiaSorin and Tecan to collaborate in new platform development
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Saluggia, Italy and Männedorf, Switzerland, June 23, 2017 - DiaSorin (FTSE Italy
Mid Cap: DIA) and Tecan Group (SIX Swiss Exchange: TECN) announced today that
they have agreed to collaborate in a development under which DiaSorin will make
use of Tecan's Fluent(®) Laboratory Automation Solution as its Nucleic Acid
extraction platform.
The new platform will be used in combination with the DiaSorin Liaison(®) MDX
PCR system to provide the customer with a complete sample to result system for
Molecular Diagnostics.
The Fluent platform, to be supplied through Tecan Partnering, will be optimized
for use with DiaSorin extraction chemistry and automated PCR set up of the
Liaison(®) MDX 96 well disc.
Fluent breaks new ground, delivering more capacity and increased speed. The
platform provides exceptional precision, throughput and walkaway time.
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and
solutions in biopharmaceuticals, forensics and clinical diagnostics. The company
specializes in the development, production and distribution of automated
workflow solutions for laboratories in the life sciences sector. Its clients
include pharmaceutical and biotechnology companies, university research
departments, forensic and diagnostic laboratories. As an original equipment
manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM
instruments and components that are then distributed by partner companies.
Founded in Switzerland in 1980, the company has manufacturing, research and
development sites in both Europe and North America and maintains a sales and
service network in 52 countries. In 2016, Tecan generated sales of
CHF 506 million (USD 511 million; EUR 464 million). Registered shares of Tecan
Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
About DiaSorin
Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is
a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the
Company has been developing, producing and marketing reagent kits for IVD
worldwide. Through constant investments in research and development, and using
its own distinctive expertise in the field of immunodiagnostics to deliver a
high level of innovation, DiaSorin offers today the broadest range of specialty
tests available in the immunodiagnostics market and new tests in the molecular
diagnostics markets, which identify DiaSorin Group as the IVD "diagnostics
specialist".
For more information, please visit www.diasorin.com
For further information:
Tecan Group
Martin Brändle
Vice President, Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor(at)tecan.com
www.tecan.com
DiaSorin
Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39 0161 487988
riccardo.fava(at)diasorin.it
DiaSorin
Ines Di Terlizzi
Investor Relator
Tel: +39 0161 487567
ines.diterlizzi(at)diasorin.it
Press Release:
http://hugin.info/100384/R/2115169/804792.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Tecan Group AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 23.06.2017 - 07:25 Uhr
Sprache: Deutsch
News-ID 549482
Anzahl Zeichen: 4096
contact information:
Town:
Maennedorf
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 445 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DiaSorin and Tecan to collaborate in new platform development"
steht unter der journalistisch-redaktionellen Verantwortung von
Tecan Group AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
